Published March 1, 2008 | Version v1
Journal article

Excellent Local Control Rates and Distinctive Patterns of Failure in Myxoid Liposarcoma Treated With Conservation Surgery and Radiotherapy

  • 1. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)
  • 2. Department of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)
  • 3. Department of Orthopaedic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)
  • 4. Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)

Description

Purpose: To evaluate the local control rates and patterns of metastatic relapse in patients with localized myxoid liposarcoma treated with conservation surgery and radiotherapy (RT). Patients and Methods: Between 1960 and 2003, 127 patients with non-metastatic myxoid liposarcoma were treated with conservation surgery and RT at our institution. The median patient age was 39 years (range, 14-79 years). Of the 127 patients, 46% underwent preoperative RT (median dose, 50 Gy) and 54% underwent postoperative RT (median dose, 60 Gy). Also, 28% received doxorubicin-based chemotherapy as a part of their treatment. Results: The median follow-up was 9.1 years. The overall survival rate at 5 and 10 years was 87% and 79%, respectively. The corresponding disease-free survival rates were 81% and 73%. The local control rate at ≥5 years was 97%. The actuarial rate of distant metastases at 5 and 10 years was 15% and 24%, respectively. Of the 27 patients who developed distant metastases, 48% did so in the retroperitoneum, 22% in other extrapulmonary soft tissues, 22% in the lung, 15% in bone, and 4% in the liver. Conclusion: The results of our study have shown that RT and conservation surgery for localized myxoid liposarcoma provide excellent local control. Distant metastatic relapse tended to occur in the retroperitoneum and other nonpulmonary soft tissues. Therefore, staging and surveillance imaging should include the abdomen and pelvis, as well as the thorax, for patients with localized myxoid liposarcoma

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2007.07.2337

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2007.07.2337;
PII
S0360-3016(07)03683-8;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
70
Journal Issue
3
Journal Page Range
p. 760-765
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
39059790
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ABDOMEN; CHEMOTHERAPY; CHEST; DOXORUBICIN; FAILURES; LIVER; LUNGS; METASTASES; PATIENTS; PELVIS; RADIATION DOSES; RADIOTHERAPY; SKELETON; SURGERY
Descriptors DEC
ANTI-INFECTIVE AGENTS; ANTIBIOTICS; ANTINEOPLASTIC DRUGS; BODY; DIGESTIVE SYSTEM; DOSES; DRUGS; GLANDS; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; RESPIRATORY SYSTEM; THERAPY

Optional Information

Copyright
Copyright (c) 2008 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.